> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lycia Therapeutics Files For Nasdaq IPO With No Revenue In 2026 After Eli Lilly Ended Its Deal
- URL: https://www.bullished.co/lycia-therapeutics-files-for-nasdaq-ipo-with-no-revenue-in-2026-after-eli-lilly-ended-its-8b49ab0a/
- Published: 2026-10-05T22:01:24.000Z
- Updated: 2026-10-05T22:01:24.000Z
- Description: The filing reports a $19.2 million first-half loss, and it leaves the share count, price range and offering size blank.
- Author: Matteo Parrino
- Tags: Deals, Industry: Not classified

Lycia Therapeutics, a South San Francisco biotech, [filed an S-1](https://www.sec.gov/Archives/edgar/data/0001806540/000162828026064973/lyciatherapeutics-drsa2.htm?ref=bullished.co) on Monday to go public on the Nasdaq Global Market under the proposed symbol LYCA. The filing shows a net loss of $19.2 million for the six months ended June 30, 2026, and no collaboration revenue in that period.

The filing says the company expects more LCA-0061 data, including from food allergy patients, but the timing is left blank in the document.

### Sources

- [S-1 — Lycia Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/0001806540/000162828026064973/lyciatherapeutics-drsa2.htm?ref=bullished.co) — SEC EDGAR